SCYNEXIS at guggenheim healthcare conference: dual-pipeline push
At a glance
- $SCYX today−2.06%last $2.85
- Vs industry peers−1.21 pts6-peer median −0.85% · behind
- Since Nov 9−18.6%from the first trade after the story
- 52-week range5.6% above low$2.70 – $9.12
- Cash runway~2 mo$8.2M cash ÷ $3.4M/mo burn · 10-Q
- Coverage0 this week2 in 30 days · too few stories to call a pace
Nothing reported about scynexis across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: Policy shifts the healthcare aisle; trial results shift individual stocks. Knowing which story you're following helps avoid confusion.
- How the stock is trading: $SCYX -2.06% in the latest session.
- Timing: It came out during market hours, so traders could react the same day, and the session move may reflect that.
Where the stock stands
SCYNEXIS ($SCYX) fell 2.06% to $2.85 in the latest session. Over the past month it is down 22.1%. It now sits 69% under the 52-week high of $9.12 and 5.6% above the year's low of $2.70, close to the bottom of its range. It has been a volatile year: the high was 3.4 times the low, so moves this size are not unusual for it.
What the filings say
In its latest report (10-Q, filed Nov 5, 2026), $SCYX lost $8.5M over the quarter to Sep 30, 2026. Operations used $30.5M of cash over the nine months to Sep 30, 2026 — about $3.4M a month — against $8.2M in cash on Sep 30, 2026. At that pace the cash covers about 2 months, which is why financing, asset sales or restructuring tend to come up for companies in this position. Total liabilities were $8.9M against $8.2M of cash on Sep 30, 2026. Its most recent filings before this story: 10-Q on Nov 5, 2026, 8-K on Sep 28, 2026, 8-K on Sep 22, 2026. Figures are as filed with the SEC; the $SCYX page has the full statements.
How much coverage it is getting
This is one of 2 stories on SCYNEXIS in Wook's last 30 days of coverage, including 0 this week. None came this week, so coverage has gone quiet. Going by their wording, 1 read bullish, 1 neutral and 0 bearish. This one reads neutral, like most of them. This is the only one from Investing.com; the rest came from other outlets.
The bigger picture
In healthcare, the calendar drives action — trial updates, FDA rulings, and pricing shifts. One drugmaker can be lifted by data; a policy change can ripple across the whole sector. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $SCYX page, and they say what management has disclosed without a reporter in between. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $SCYX is from its high or compare this week's coverage with earlier weeks.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on November 9, 2026. $SCYX has moved -18.57% ($3.50 to $2.85). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
